SecBot SecBot
SECBOTREPLAY Home › Report › HCM

HCM · HUTCHMED filed a routine 6-K disclosing that its Chairman, Dr

HUTCHMED (China) Ltd · 6-K filed Aug 18, 2026 at 06:12 ET

At the news

NEUTRALIMPACT 2/10

6-K filed Aug 18, 2026 at 06:12 ET

HUTCHMED filed a routine 6-K disclosing that its Chairman, Dr. Dan Eldar, was formerly a director of S.D. Sight Diagnostics Ltd., which entered insolvency proceedings in Israel. The filing explicitly states the insolvency does not involve HUTCHMED or its operations, and the amount involved (~$1M) is immaterial relative to HUTCHMED's $2.1B market cap. This is a purely administrative AIM Rule disclosure with no financial or operational impact on the company.

  • Chairman Dr. Dan Eldar was a director of S.D. Sight Diagnostics from Dec 2018 to Mar 2026.
  • S.D. Sight entered insolvency proceedings in Israel; a trustee was appointed on May 28, 2026.
  • The amount involved is approximately NIS 3,057,876 (~US$1,019,292).
  • Neither S.D. Sight nor Hutchison Water Israel E.P.C Ltd (which holds ~9.98% of S.D. Sight) is part of HUTCHMED.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access